Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

None had been diagnosed with Alzheimer disease and related dementias at the start of the study. The researchers discovered that people who took GLP-1 receptor agonists (like Ozempic) or a type of ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

Newsweek has contacted Ozempic manufacturer Novo Nordisk for ... GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias. JAMA Neurology.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been hailed ... seems to be promising in reducing the risk of Alzheimer's disease and related dementias (ADRD)'.

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...